Nadia Sellami, PhD, global segment lead for gene and cell therapy at PacBio, talks about long-read sequencing for cell and gene editing in a video interview.
At the American Society of Gene and Cell Therapy (ASGCT) conference in Baltimore, Md. in May 2024, Pharmaceutical Technology® sat down with Nadia Sellami, PhD, global segment lead for gene and cell therapy at PacBio, about the benefits of long-read sequencing in cell and gene editing.
According to Sellami, long-read sequencing detects information that short-read sequencing cannot capture. “And in contrast to other long-read sequencing methods, it has higher accuracy while maintaining the same read length,” she says in this video interview. “So, for example, you can see long indels that you might get from gene editing. You can sequence the entire AAV [adeno-associated virus] molecule, ITR [inverted terminal repeat sequence] to ITR. You can sequence plasmids. You can sequence full length mRNA [messenger RNA] and so many more sequencing applications.”
DNA sequencing is important for the design, production, and quality of gene therapies, says Sellami. Click the video box above to view the full interview.
For more coverage from the 2024 ASGCT conference, visit PharmTech.com’s conference page to view the following:
Exosomes Field Advances with Milestones Achieved by EXO Biologics and ExoXpert
December 4th 2024EXO Biologics and ExoXpert, an EXO Biologics subsidiary, have received GMP certification of a European manufacturing facility for exosomes and have successfully loaded mRNA and DNA payloads into GMP-grade exosomes for drug delivery.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.